NCT02300103 - Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2014

Primary Completion Date

July 2, 2016

Study Completion Date

September 15, 2016

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

SOF/VEL

400/100 mg FDC tablet administered orally once daily

DRUG

RBV

Tablet (s) administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (30)

Unknown

San Diego

San Marcos

Aurora

Gainesville

Jacksonville

Miami

Orlando

Wellington

Baltimore

Boston

Hillsborough

Manhasset

Durham

Fayetteville

Philadelphia

Pittsburgh

Germantown

Nashville

Dallas

San Antonio

Falls Church

Norfolk

Richmond

Darlinghurst

Fitzroy

Melbourne

Murdoch

Auckland

Christchurch

San Juan